WASHINGTON, March 31 (UPI) — The U.S. Food and Drug Administration says it’s evaluating a clinical trial that suggests taking Stalevo may place people at risk of getting prostate cancer.
Stalevo (entacapone) is used to treat symptoms of Parkinson’s disease. The long-term trial suggested the drug might increase a patient’s risk of developing prostate cancer, although other controlled clinical trials didn’t find such a linkage, the FDA said.
“FDA is still reviewing the available information and has not concluded Stalevo increases the risk of developing prostate cancer,” officials said in a statement. “Healthcare professionals should be aware of this possible risk and follow current guidelines for prostate cancer screening.”
The federal agency said patients shouldn’t stop taking their medication unless directed to do so by their healthcare professional.
Copyright 2010 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI’s prior written consent.